WO2006053186A2 - Methode de traitement de troubles moteurs - Google Patents

Methode de traitement de troubles moteurs Download PDF

Info

Publication number
WO2006053186A2
WO2006053186A2 PCT/US2005/040877 US2005040877W WO2006053186A2 WO 2006053186 A2 WO2006053186 A2 WO 2006053186A2 US 2005040877 W US2005040877 W US 2005040877W WO 2006053186 A2 WO2006053186 A2 WO 2006053186A2
Authority
WO
WIPO (PCT)
Prior art keywords
myoclonus
compound
patient
formula
tremor
Prior art date
Application number
PCT/US2005/040877
Other languages
English (en)
Other versions
WO2006053186A3 (fr
Inventor
Steven Frucht
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Priority to US11/667,530 priority Critical patent/US20090137565A1/en
Priority to MX2007005679A priority patent/MX2007005679A/es
Priority to CA002586975A priority patent/CA2586975A1/fr
Priority to AU2005304352A priority patent/AU2005304352A1/en
Priority to EP05847768A priority patent/EP1809286A4/fr
Priority to JP2007541338A priority patent/JP2008519847A/ja
Publication of WO2006053186A2 publication Critical patent/WO2006053186A2/fr
Publication of WO2006053186A3 publication Critical patent/WO2006053186A3/fr
Priority to IL182906A priority patent/IL182906A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Definitions

  • This invention relates to methods for treatment of movement disorders such as hyperkinetic movement disorders, tics, and chorea. More particularly, the invention relates to treatment of myoclonus, dystonia and essential tremor by administrating compounds of formula (I), defined herein. Such compounds include sodium gamma- hydroxybutyrate (Xyrem ® ). Background of the Invention
  • Movement disorders encompass a wide variety of neurological conditions affecting motor control and muscle tone. These conditions are typified by the inability to control certain bodily actions. Accordingly, these conditions pose a significant quality of life issue for patients.
  • Nonlimiting examples of movement disorders include Parkinson's syndrome, dyskinesias, dystonias, myoclonus, chorea, tics, and tremor.
  • Dystonia one type of movement disorder, is a neurological disorder characterized by sustained, involuntary movements. These movements typically produce twisting postures. Dystonia is also known as torsion dystonia. A large number of conditions produce dystonia, including genetic causes, toxin or drug-induced causes, and degenerative illnesses in which dystonia is manifested.
  • Essential tremor is another type of movement disorder, separate from dystonia. It is the most common cause of tremor in the adult population, affecting approximately five to ten million Americans. Patients with essential tremor exhibit i involuntary, rhythmic tremor, or shaking, of a body part. Commonly, essential tremor affects the hands, head, or voice, but it can also affect the tongue, legs, or trunk. The tremor of one body part can occur alone or in combination with other body parts. Depending on its severity, essential tremor can escalate from being merely a slight disturbance to a functional disability and physical handicap. Especially where tasks involve fine motor control, patients with essential tremor may have difficulty performing these skills. For example, a severe tremor in the hands makes eating, drinking, writing, and dressing difficult. Tremors associated with essential tremor typically worsen over time. While the exact cause of essential tremor is not known, it is often inherited.
  • Myoclonus is yet another form of movement disorder, characterized by very fast, lightning-like jerks, caused by brief, sudden muscle contractions (positive myoclonus) or relaxations (negative myoclonus).
  • the shock-like involuntary movements of myoclonus are often severe enough to interfere with the basic activities of daily living. These jerks may affect any part of the body. Some myoclonic movements occur in response to stimulus, while others occur when making a movement. Still other myoclonic movements occur spontaneously.
  • Myoclonus occurs as a result of any number of conditions affecting the central nervous system, including genetic disorders (e.g., essential myoclonus), drug and toxin-induced conditions, after cardiac arrest (e.g., posthypoxic myoclonus), and as the result of progressive neurological degenerative disorders (e.g., multiple sclerosis, Alzheimer's disease or Creutzfeldt- Jakob disease).
  • genetic disorders e.g., essential myoclonus
  • drug and toxin-induced conditions e.g., after cardiac arrest (e.g., posthypoxic myoclonus), and as the result of progressive neurological degenerative disorders (e.g., multiple sclerosis, Alzheimer's disease or Creutzfeldt- Jakob disease).
  • myoclonus with dystonia also known as essential myoclonus, is a rare, genetic form of myoclonus.
  • alcohol responsive myoclonus with dystonia is completely resistant to all other treatments and isakily responsive to alcohol.
  • Another type of myoclonus is an often- devastating, rare neurologic disorder that follows an episode of oxygen deprivation to the brain, such as following cardiac or respiratory arrest, or following kidney or liver failure.
  • Some patients who survive such trauma have normal mentation but develop severe involuntary movements.
  • Attempts to perform manual tasks or to walk typically trigger intractable action and intention myoclonus.
  • Negative myoclonic jerks often affect muscles of postural support, producing a characteristic bouncing gait which may render a patient wheelchair-bound.
  • cortical and subcortical foci may be responsible for generating myoclonic jerks, hi a recent study using positron emission tomography, a characteristic pattern of ventrolateral thalamic activation in posthypoxic patients that was absent in controls was demonstrated.
  • Treatment of posthypoxic myoclonus relies on medications, which are only partially effective.
  • Treatment with anti-myoclonic agents such as clonazepam, valproic acid, levetiracetam or zonisamide is sometimes helpful, however many patients benefit incompletely and others are left in a totally dependent state.
  • Movement disorders such as myoclonus, dystonia, chorea, tics, and essential tremor are treated with benzodiazepines, anticonvulsants and ⁇ -adrenergic blockers.
  • Other therapies used for movement disorders, particularly dystonia, include anticholinergics and doparnine-blocking or deleting agents. The effectiveness of these agents is diminished, however, because not all patients respond well to the drug therapy, some of the drugs are not well tolerated, and the drugs may cause undesirable side effects. Additionally, in some cases, patients develop tolerance to the drugs, requiring ever increasing dosages to ameliorate the symptoms.
  • Surgery such as thalamotomy pallidotomy and deep brain stimulation, are also used to treat hyperkinetic movement disorders. However, because of their invasive nature, these treatment options are less desirable. Therefore, a need exists for alternative drug-based therapies for movement disorders such as hyperkinetic movement disorders that do not pose the drawbacks of the present therapies.
  • alcohol produces a euphoric effect at the doses typically needed to produce relief of tremor or myoclonus.
  • Further drawbacks to treatment with alcohol include gastroesophageal erosion with chronic use, increased risk of liver toxicity including the possibility of cirrhosis, caloric and sugar intake which may be contraindicated in patients with obesity and diabetes, and health concerns in patients with cardiac disease.
  • a single patient with alcohol- responsive myoclonus with dystonia was recently reported to display improved myoclonus when treated with sodium gamma-hydroxybutyrate, an approved medication that is similar to alcohol in its effects on the nervous system.
  • the present invention provides methods of treating involuntary movement disorders that are presently untreatable, or inadequately treated by best medical therapy.
  • the present invention provides a therapeutic method to treat movement disorders comprising administering a compound of formula (I):
  • n 1-2
  • X is H, a pharmaceutically acceptable cation or (C 1 -C 4 )alkyl
  • Y is hydroxy, (C 1 -C 4 )alkoxy, CH(Z)CH 3 , (C 1 -C 4 )alkanoyloxy, phenylacetoxy, or benzoyloxy or where X and Y are connected by a single bond, wherein Z is hydroxy, (C 1 -C 4 )alkoxy, (C 1 - C 4 )alkanoyloxy, phenylacetoxy, or benzoyloxy.
  • the movement disorder is a hyperkinetic movement disorder such as myoclonus
  • the myoclonus is not alcohol responsive myoclonus with dystonia.
  • the myoclonus is posthypoxia myoclonus or is not alcohol responsive posthypoxia myoclonus
  • the movement disorder is essential tremor.
  • the amount of one or more of the compounds of formula (I) is effective to eliminate or alleviate at least one of the symptoms of myoclonus or essential tremor.
  • symptoms include, but are not limited to negative myoclonus, myoclonus at rest, stimulus-sensitive myoclonus, action myoclonus, benign tremor, postural tremor, and kinetic tremor.
  • the present invention also provides a therapeutic method to treat hyperkinetic movement disorders including administering to a human afflicted with a myoclonus an effective amount of a compound of formula (I), wherein the amount is effective to alleviate at least one symptom of the myoclonus, wherein the myoclonus is not alcohol-sensitive essential myoclonus with dystonia.
  • myoclonus include palatal myoclonus, a startle syndrome, and spinal myoclonus.
  • the present invention further provides a therapeutic method to treat a hyperkinetic movement disorder including administering to a human afflicted with a dystonia, essential tremor, cerebellar tremor, a tic, chorea (such as Huntington's disease), ballismus, progressive myoclonic epilepsy, focal task-specific dystonia, and brainstem myoclonus an effective amount of a compound of formula (I), wherein the amount is effective to alleviate at least one symptom of the myoclonus, wherein the myoclonus is not alcohol-sensitive essential myoclonus with dystonia.
  • dystonia include generalized dystonia and focal dystonia.
  • Other compounds that can be used in the present methods include those disclosed in Kluger (U.S. Patent Nos. 4,599,355 and 4,738,985).
  • prodrugs of gamma-hydroxyburic acid are also useful in the practice of the invention, including 1,4- butane diol, 4-hydroxyvaleric acid, ⁇ -valeroacetone, trans-4-hydroxy-crotonic acid, 4-methyl- 4hydroxycrotonic acid, and trans-4-phenyl-hydroxycrotonic acid and their salts.
  • prodrugs of gamma-hydroxyburic acid include 1,4- butane diol, 4-hydroxyvaleric acid, ⁇ -valeroacetone, trans-4-hydroxy-crotonic acid, 4-methyl- 4hydroxycrotonic acid, and trans-4-phenyl-hydroxycrotonic acid and their salts.
  • treatment of patients with sodium oxybate alleviates symptoms of movement disorders, particularly hyperkinetic movement disorders such as myoclonus, dystonia, chorea, tics, and essential tremor.
  • movement disorders particularly hyperkinetic movement disorders such as myoclonus, dystonia, chorea, tics, and essential tremor.
  • this effect was observed in a patient with severe posthypoxic myoclonus whose movements were refractory to all available anti-myoclonic agents.
  • Figure 1 is a graphical representation of Unified Myoclonus Rating Scale
  • Figure 2 is a photograph of a patient after treatment using chopsticks at the beginning of her treatment with 4 gm of Xyrem ® twice daily.
  • Figure 3 is a photograph of a letter written by the patient shown in Figure 2, on her own initiative, and without assistance, after treatment with Xyrem ® .
  • Figure 4 depicts spirals drawn by patients having ET before and after receiving sodium oxybate. Pre- and post-treatment spirals are shown for patient #4 (PME), (A: pre-treatment; B: post-treatment (2.5 gm TED)), and patient #18 (ET), (C: pre-treatment; D: post-treatment 3 gm TID).
  • PME pre-treatment
  • E post-treatment
  • C pre-treatment
  • D post-treatment 3 gm TID
  • carrier is used herein to refer to a pharmaceutically acceptable vehicle for a pharmacologically active agent.
  • the carrier facilitates delivery of the active agent to the target site without terminating the function of the agent.
  • suitable forms of the carrier include solutions, creams, gels, gel emulsions, jellies, pastes, lotions, salves, sprays, ointments, powders, solid admixtures, aerosols, emulsions (e.g., water in oil or oil in water), gel aqueous solutions, aqueous solutions, suspensions, liniments, tinctures, and patches suitable for topical administration.
  • compositions of a compound include acid and base addition salts thereof. Suitable acid addition salts are formed from acids that form non-toxic salts. Nonlimiting examples include hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1-methylene-bis- (2-hydroxy-3-naphthoate)) salts.
  • Suitable base salts are formed from bases which form non ⁇ toxic salts.
  • Nonlimiting examples include aluminum, sodium, potassium, calcium, magnesium, zinc and diethanolammonium salts.
  • suitable salts see, e.g., Berge et ah, J. Pharm. Sd. 66:1-19 (1977) and Remington: The Science and Practice of Pharmacy, 20th Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
  • Pharmaceutically acceptable esters include those esters that retain, upon hydrolysis of the ester bond, the biological effectiveness and properties of the carboxylic acid and are not biologically or otherwise undesirable.
  • esters are typically formed from the corresponding carboxylic acid and an alcohol. Generally ester formation can be accomplished via conventional synthetic techniques. (See, e.g., March's Advanced Organic Chemistry, 3 rd Ed., John Wiley & Sons, New York p.
  • the alcohol component of the ester will generally comprise (i) a C 2 -C 12 aliphatic alcohol that optionally contains one or more double bonds and optionally contains branched carbons or (ii) a C 7 -C 12 aromatic or heteroaromatic alcohol.
  • This invention also contemplates the use of those compositions which are both esters as described herein and at the same time are the pharmaceutically acceptable salts thereof.
  • the term "effective" is used herein to indicate that the active agent is administered in an amount and at an interval that results in the desired treatment or improvement in the disorder or condition being treated (e.g., an amount effective to decrease at least one myoclonic or tremor symptom).
  • GLB Gamma-hydroxybutyric acid
  • GHB is a short-chain fatty acid, structurally closely related to gamma- aminobutyric acid (GABA).
  • GABA gamma- aminobutyric acid
  • GABA is the precursor of GHB, and it is synthesized in presynaptic neuronal terminals.
  • GHB A specific, high-affinity receptor for GHB is present in the brain in highest density in the hippocampus, cortex and thalamus. GHB may act at both its own receptor and at the GABA-B receptor, directly stimulating the former or indirectly the latter after undergoing conversion to GABA. Id.
  • Xyrem ® is approved specifically for use in narcoleptic patients with cataplexy. All patients treated with Xyrem ® in the United States are enrolled in the Xyrem ® Success Program, a safety and monitoring system that ensures that the drug is being used and handled appropriately. Fuller D.E., et al, Drug Saf. 27:293-306 (2004). When administered correctly, the drug is safe and well tolerated. Sleep 25:42-49 (2002).
  • Xyrem ® sodium oxybate
  • Xyrem ® sodium oxybate
  • Xyrem ® is a central nervous system depressant with anti-cataplectic activity.
  • Xyrem ® is a white powder that is given by mouth in liquid form, dissolved in water. It is metabolized to carbon dioxide and water, has no active metabolites and does not alter the activity of the cytochrome P450 system.
  • a total of 448 patients with narcolepsy received Xyrem ® in clinical trials.
  • the approved indication for Xyrem the drug is given at a starting dose of 4.5 gm per night in two equally divided doses.
  • the first dose of Xyrem ® is given at bedtime, several hours after a meal, and the second dose is given 2 1/2 to 4 hours later (the patient is awakened).
  • the dose may be increased to a maximum of 9 gm per day over eight weeks in increments of 1.5g per day.
  • GHB and ⁇ -butyrolactone are available from the Aldrich Chemical Co., Milwaukee, Wis., and can be employed to prepare other compounds within the scope of formula (I).
  • the compound can be esterified with (C 1 -C 4 )alkanols and alkanoylated or benzoylated with alkanoyl and benzoyl chloride or anhydrides.
  • the cation can also be readily exchanged to replace sodium with other metal or organic cations, such as Ca + , K + , Li + , or (R) 4 N + wherein each R is H, phenyl, (C 1 -C 6 )alkyl or hydroxy ⁇ - C 6 )alkyl, i.e., ammonium or hydroxyethyl amine salts.
  • metal or organic cations such as Ca + , K + , Li + , or (R) 4 N + wherein each R is H, phenyl, (C 1 -C 6 )alkyl or hydroxy ⁇ - C 6 )alkyl, i.e., ammonium or hydroxyethyl amine salts.
  • the present invention is directed to methods for treating movement disorders such as hyperkinetic movement disorders by administering to a patient a compound of formula (I).
  • movement disorders contemplated by the invention include myoclonus, dystonia, chorea, tics, and tremor, including essential tremor.
  • the various types of myoclonus are categorized based on the physiology of the disease (cortical, subcortical, spinal, peripheral), clinical manifestations (anatomic distribution, provocative factors, contraction patterns) and also the cause of the myoclonic movements (physiologic, essential myoclonus, myoclonic epilepsy, secondary myoclonus).
  • cortical myoclonus arises from the sensorimotor cortex and is typified by the regular rhythms of their jerking movements.
  • Subcortical myoclonus arises from damage to the thalamus or brainstem.
  • Myoclonus can be focal (affecting a specific body part), segmental (affecting parts of the body that are near each other), multifocal or generalized.
  • Some myoclonic movements are spontaneous while others occur in response to stimulus (reflex or stimulus-sensitive).
  • Action or intention myoclonus occurs during voluntary movements or the intention to move.
  • the contraction patterns of myoclonic movement can be rhythmic, arrhythmic, or oscillatory, hi one embodiment, the myoclonus is not alcohol sensitive essential myoclonus-dystonia.
  • the myoclonus is posthypoxic myoclonus or not alcohol responsive posthypoxic myoclonus.
  • the patient exhibits one or more of the following: negative myoclonus, myoclonus at rest, stimulus-sensitive myoclonus and action myoclonus, hi yet further embodiment, the myoclonus is palatal myoclonus, a startle syndrome, spinal myoclonus, progressive myoclonic epilepsy, and brainstem myoclonus.
  • Tremor also encompasses a variety of types. Kinetic or intention tremor occurs during voluntary movement. Postural tremor, one type of kinetic tremor, occurs when attempting to maintain a fixed position against gravity, such as outstretched arms. Internal tremor is a general vibrating sensation. Typically, tremors disappear during sleep. Tremor is evaluated by determining the distribution of the tremor, the type and how it occurs, intensity and frequency, contraction pattern and degree of functional performance. In some embodiments, the patient exhibits one or more of the following: enhanced physiologic tremor, postural tremor, or kinetic tremor.
  • the invention is also directed to treatment of dystonia, cerebellar tremor, a tic or chorea with compounds of formula (I).
  • the various types of dystonia are characterized based on anatomical distribution. For example, focal dystonia is limited to one area of the body, whereas segmental and multifocal dystonias affect two or more areas of the body (nearby/contiguous and more distant, respectively). Hemidystonia affects one half of the body, while generalized dystonia involves leg movement in additional to one or more other regions of the body.
  • focal dystonia include, without limitation, cervical dystonia/blepharospasm, oromandibular dystonia, laryngeal dystonia, and limb dystonia.
  • dystonia With primary, or idiopathic, dystonia, the dystonia is present without other neurologic abnormalities, and secondary causes are ruled out, with the exception of tremor.
  • Other classifications for dystonia include secondary (sympathetic) dystonia, dystonia-plus syndromes (e.g., dystonia with myoclonus), and heredodegenerative dystonia.
  • the invention is further directed to focal-task dystonia.
  • Chorea is an involuntary, non-rhythmical movement of moderate speed and amplitude that passes quickly and randomly from one part of the body to the other. It may involve the face and limbs, and can result in the inability for a patient to maintain posture. Chorea occurs in patients with drug-induced disorders or hereditary diseases, such as Huntington's disease.
  • Ballismus consists of irregular and unpredictable movements that can be high in amplitude and velocity. In most subjects, ballismus is limited to one side of the body and can be caused by a focal destructive lesion of the contralateral subthalamic nucleus. It is often referred to as hemiballismus.
  • Tics comprise abnormal, repetititve movements or sounds, which are subsequently classified as motor tics and vocal tics, respectively. These impulsive actions are random and variable in pattern.
  • Non-limiting examples of tics include facial movement, repetitive eye blinks, head shakes, and vocalizations.
  • Tourette's syndrome is the best-known condition characterized by vocal and motor tics.
  • the subject is a mammal.
  • mammals include: human, primate, mouse, otter, rat,.and dog.
  • the invention also provides methods for ameliorating one or more movement disorders by administering to a patient a compound of formula (I), hi one embodiment, the invention provides methods for ameliorating one or more myoclonic movements by administering to a patient a compound of formula (T).
  • myoclonic movements include: negative myoclonus, myoclonus at rest, stimulus-sensitive myoclonus, action myoclonus, alcohol responsive posthypoxic myoclonus, palatal myoclonus, a startle syndrome, and spinal myoclonus.
  • the functional performance of a patient diagnosed with myoclonus is improved by administering to the patient a compound of formula (T).
  • the amelioration of myoclonic movements and the improvement of functional performance are assessed by use of the Unified Myoclonus Rating Scale. In another embodiment, the amelioration of myoclonic movements and the improvement of functional performance are assessed by use of the Chadwick-Marsden Scale.
  • Amelioration of one or more tremors is achieved by administering to a patient a compound of formula (T).
  • tremors ameliorated by administration of a compound of formula (I) include without limitation: hand tremor, arm tremor, voice tremor, head tremor, trunk tremor and/or leg tremor.
  • Amelioration is assessed by use of tremor classification scales known to persons skilled in the art, such as the Collaborative Clinical Classification of Tremor, the Classification of Essential Tremor (Tremor Research Investigation Group) or the WHIGET (Washington Heights Inwood Genetic Essential Tremor) Rating Scale.
  • Amelioration of dystonia, cerebellar tremor, a tic or chorea is achieved by administrating to a patient a compound of formula (T).
  • Examples of dystonias ameliorated by administration of a compound of formula (I) include generalized dystonias, focal dystonias, action dystonia, task-specific dystonia, rest dystonia, segmental dystonias, multifocal dystonias, hemidystonia, cervical dystonia, blepharospasm, oromandibular dystonia, laryngeal dystonia, and limb dystonia.
  • Amelioration of dystonia, cerebellar tremor, a tic or chorea is assessed by methods known to those of skill in the art.
  • the compounds of formula (T) such as 4-hydroxybutyric acid salts
  • the active ingredient may be administered as the pure chemicals, as by inhalation of a fine powder via an insufflator
  • the active ingredient is preferable to present the active ingredient as a pharmaceutical formulation.
  • the invention thus, further provides a pharmaceutical formulation comprising a compound of formula (I), together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients.
  • the cations and carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions include those suitable for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration.
  • forms suitable for parenteral administration also include forms suitable for administration by inhalation or insufflation or for nasal, or topical (including buccal, rectal, vaginal and sublingual) administration.
  • the formulations may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combinations thereof, and then, if necessary, shaping the product into the desired delivery system.
  • compositions suitable for oral administration may be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tables each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion; or in a chewable base such as a synthetic resin or chicle for ingestion of the active ingredient from a chewing gum.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
  • the tablets may be coated according to methods well known in the art, i.e., with enteric coatings.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, flavoring, emulsifying agents, non ⁇ aqueous vehicles (which may include edible oils), or preservatives.
  • the compounds according to the invention may also be formulated for parenteral administration ⁇ e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre-filled syringes, small volume infusion containers or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • compound(s) of formula (I) may be formulated as ointments, creams or lotions, or as the active ingredient of a transdermal patch.
  • Suitable transdermal delivery systems are disclosed, for example, in A. Fisher et al, (U.S. Patent No. 4,788,603), Chien et al, (U.S. Patent No. 5,145,682) or R. Bawa et al, (U.S. Patent Nos. 4,931,279, 4,668,506 and 4,713,224).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents.
  • the active ingredient can also be delivered via iontophoresis, e.g., as disclosed in U.S. Patent Nos. 4,140,122, 4,383,529, or 4,051,842.
  • Formulations suitable for topical administration in the mouth include unit dosage forms such as lozenges comprising active ingredient in a flavored base, usually sucrose and acadia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; mucoadherent gels, and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • the above-described formulations can be adapted to give sustained release of the active ingredient employed, e.g., by combination with certain hydrophilic polymer matrices, e.g., comprising natural gels, synthetic polymer gels or mixtures thereof.
  • compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • the compounds according to the invention are conveniently delivered form an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the invention may take the form of a dry powder composition, for example, a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • the compounds of the invention may be administered via a liquid spray, such as via a plastic bottle atomizer.
  • a liquid spray such as via a plastic bottle atomizer.
  • Typical of these are the Mistometer ® (Winthrop) and the Medihaler ® (Riker).
  • compositions according to the invention may also contain other adjuvants such as flavorings, colorings, antimicrobial agents, or preservatives.
  • the methods for treating movement disorders according to the invention may also include co-administration of a compound of formula (I) with one or more anti- myoclonic, anti-tremor, anti-chorea, anti-tic, or anti-dystonia agents.
  • the compounds are co-administered simultaneously.
  • the compounds are co-administered sequentially.
  • Anti-myoclonic and anti-tremor agents are well known to those of skill in the art. For example, benzodiazepines, anticonvulsants, and ⁇ -adrenergic blockers are known to be effective in treating myoclonus and essential tremor and are suitable for co-administration with GHB.
  • GABA receptor agonists are suitable for co ⁇ administration with GHB.
  • anti-myoclonic agents include, without limitation, clonazepam, levetiracetam, valproic acid, phenobarbital, topiramate, zonisamide, primidone, phenytoin, 5-hydroxytryptophan, piracetam, acetazolamide, baclofen, fluoxetine, propranolol, lamotrigine, sumatriptan, tetrabenazine, trihexyphenidyl, melatonin, and alprazolam.
  • anti-tremor agents include, without limitation, mysoline, propranolol, primidone, benzodiazepines (clonazepam, lorazepam, alprazolam, diazepam) nadolol, methazolamide, gabapentin, topiramate, levetiracetam and botulinum toxin.
  • benzodiazepines clonazepam, lorazepam, alprazolam, diazepam
  • nadolol methazolamide
  • gabapentin gabapentin
  • topiramate topiramate
  • levetiracetam botulinum toxin.
  • anti-chorea medications include haloperidol, reserpine, tetrabenazine, and valproic acid.
  • Anti-tic medications include, but are not limited to clonidine, clonazepam, guanfacine, haloperidol, pimozide, and tetrabenazine. It will be appreciated that the compound of formula (I) and the co-administered agent can be prepared in a single pharmaceutical composition or can be administered as separate pharmaceutical compositions.
  • anti-dystonia agents include, without limitation, dopaminergic drugs (e.g., dopamine agonists, dopamine-blocking agents, dopamine-depleting agents, tetrabenasize with or without lithium, clozapine, olanzapine), botulinum toxin, and benzodiazepines (diazepam, clonazepam, lorazepam, alprazolam,), baclofen, and anticholinergics (trihexyphenidyl, diphenhydramine) .
  • dopaminergic drugs e.g., dopamine agonists, dopamine-blocking agents, dopamine-depleting agents, tetrabenasize with or without lithium, clozapine, olanzapine), botulinum toxin, and benzodiazepines (diazepam, clonazepam, lorazepam, alprazolam,),
  • the amount of the compound of formula (I) required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the severity of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
  • a suitable dose will be in the range of that shown to be effective as a hypnotic agent, i.e., to treat narcolepsy, of from about 1-500 mg/kg, e.g., from about 10-250 mg/kg of body weight per day, such as 25 to about 200 mg per kilogram body weight of the recipient per day.
  • a total daily dosage of 500 mg - 20 g is administered.
  • a total daily dosage of 2-12 g is administered.
  • the total daily dosage is about 4.5 g.
  • the total daily dosage is 4, 6, or 8 g.
  • the compound of formula (I) is administered twice daily, hi other embodiments, the compound of formula (I) is administered three times daily.
  • the compound is conveniently administered in unit dosage form; for example, containing 0.5-20 g, conveniently 1-7.5 g, most conveniently, 2-5 g, of active ingredient per unit dosage form.
  • the total daily dosage i. e. , of about 500 mg - 20 g is administered three or more times daily for about 1-4 months or longer, as needed. In other embodiments, the total daily dosage is administered chronically, i.e., with no time limit for ending the therapy.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more doses or sub-doses per day.
  • the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations such as teaspoons of a liquid composition or multiple inhalations from an insufflator, hi one embodiment, a dose of 1-4 g is administered twice daily.
  • the subject receives a dose of 2 grams per night. After a period of time to adjust to the medication (e.g., 2 weeks), an assessment is performed to determine whether or not the myoclonus is still present and troublesome. If so, the dose is increased to 4 grams per night. After another period of time to adjust to the medication, ⁇ e.g., another 2 weeks), a similar assessment is made, and if needed the dose is increased to 6 grams per night. The dose is further increased in similar fashion as needed.
  • the compound of formula (I) When the compound of formula (I) is administered once daily, the compound is administered in the morning, afternoon, evening or night before bedtime. Because hyperkinetic movement disorders disappear during sleep, administration during the day allows for observation of the effects of the drug.
  • the first dose When administered twice daily, the first dose is administered in the morning or, alternatively, in the afternoon. The second dose is administered approximately 6-12 hours later. For example, in the afternoon, evening or nighttime before bed.
  • the patient was referred to the Columbia University Medical Center Movement Disorder Center for evaluation of severe posthypoxic myoclonus at the age of 37.
  • She underwent an elective uterine fibroid myomectomy that was complicated by an anesthesia accident.
  • the duration of hypoxia or cardiac arrest was unknown; however, frequent tonic-clonic seizures were noted immediately in the post ⁇ operative period.
  • She remained comatose and intubated, and subsequently required a tracheotomy and feeding tube.
  • Myoclonic jerks and electrographic seizures were noted in the intensive care unit. She developed severe, debilitating myoclonus following the anesthesia accident.
  • Anti-myoclonic medications on initial evaluation included clonazepam (3 mg daily) and levetiracetam (2,500 mg daily).
  • Neurologic examination revealed a thin cooperative woman with obvious severe myoclonic jerks. Detailed mental status examination was hampered by severe myoclonic speech; however, she answered all questions appropriately and followed complex commands without difficulty. By her family's report, her short-term and long-term memory were not impaired. At rest, positive myoclonic jerks of the arms, legs and trunk were evident. These jerking motions were exacerbated when the patient attempted voluntary movement, affecting in particular the proximal area of the arms. Negative myoclonic jerks were frequent, affecting the arms and wrists in outstretched posture.
  • section I patient questionnaire (11 items); section II: myoclonus at rest (frequency and amplitude, 16 items); section III: stimulus-sensitive myoclonus (17 items); section IV: severity of myoclonus with action (frequency and amplitude, 20 items); section V: performance on functional tests (5 items); section VI: physician rating of patient's global disability (1 item); section VII: presence of negative myoclonus (1 item); section VIII: severity of negative myoclonus (1 item). Each item is rated on a scale of 0 to 4, with higher scores assigned to myoclonus of greater severity or frequency.
  • section III stimulus-sensitivity is either present (1) or absent (0); section VII negative myoclonus either present (1) or absent (0); and section VIII negative myoclonus absent (0) to severe (3).
  • AU office visits and the UMRS scale were performed by the supervisory physician.
  • the patient came to the office for five visits, each separated by two weeks (time 0, 2 weeks, 4 weeks, 6 weeks and 8 weeks).
  • the physician examined the patient, and inquired about any adverse events.
  • the physician performed the UMRS while the patient was videotaped.
  • Xyrem ® was dispensed by the physician at each visit.
  • a movement disorder neurologist blinded to the trial design scored videotapes of the baseline visit, 2 gm, 3 gm, 4 gm (first) and 4 gm (second) visits in random order.
  • the blinded rater was not provided with treatment scores of section I of the UMRS (patient self-assessment) in order to maintain the rating blind. Scores for each section were calculated as described previously.
  • Thompson SJ., et al Adv Neurology Vol. 89. Lippincott Williams and Wilkins, Philadelphia, 2002:361-376.
  • Scores of each subsection of the UMRS are presented in Table 1 and plotted in Figure 1.
  • the scores reflect the intensity and the frequency of the myoclonic movement.
  • Lower scores indicate a lower occurrence and intensity of the jerking movement.
  • the data presented in Figure 1 demonstrates the % of the maximum score for each UMRS subsection at each dosage level. For example, at a dosage level of 0 gm/day, the score of subsection II was 3, which is 75% of the maximum score of 4.
  • myoclonus at rest (section II) dramatically diminished after 2 gm of GHB and disappeared at higher doses. Stimulus-sensitive myoclonus (section III) improved comparably.
  • the clinical trial was designed with a very slow titration schedule, in order to prevent possible side effects such as sedation, worsening of ataxia or orthostasis. Like most forms of myoclonus, posthypoxic myoclonus disappears during sleep and it is therefore necessary to administer the drug during waking hours in order to observe its effects. The patient was able to tolerate two daytime doses of 4 gm of GHB without significant sedation, even with concurrent treatment with clonazepam and levetiracetam.
  • myoclonus subscore measures both the frequency and amplitude of myoclonus triggered by movements of the face, neck, trunk, arms and legs, as well as myoclonus triggered by arising, standing and walking.
  • limb ataxia may inadvertently contribute to the scores of arm and leg movements on part IV of the scale.
  • a breakdown in fluency of movement on finger to nose or heel to shin testing may be attributed to myoclonus, when in fact the deficits arise from underlying cerebellar dysfunction.
  • Many patients with posthypoxic myoclonus have mild cerebellar deficits (Agarwal P., et at, Curr. Opin. Neurol. 16:515-521 (2003)), and section IV of the UMRS is not designed to parse out these components. In contrast, improvements in functional performance observed in section V were more dramatic.
  • a short double-blind, placebo-controlled protocol will be performed with approximately 20 patients, followed by an open-label extension.
  • the protocol will call for a titration up to 6.125 gm per day in the double-blind phase, with the option of titrating up to 9 gm per day in the open-label phase.
  • the study is a double-blind, randomized, placebo-controlled, parallel- group, dose ranging trial of GHB for dystonia.
  • the study population includes patients with clinically significant myoclonus-dystonia.
  • the primary objectives include: 1) To assess the safety and tolerability of GHB in dystonia patients and 2) To assess the efficacy of GHB in treating dystonia.
  • the secondary objectives are: 1) To assess the effect of dosing of GHB on dystonia.
  • the duration of the double-blind portion of the study is 8 weeks.
  • the duration of the fixed-dose portion of the study is 8 weeks.
  • the duration of the dose-ranging portion of the study would be an extended period, perhaps as long as one year.
  • patients In order to qualify for this study, patients must meet the following criteria: 1) Men and women, diagnosed with dystonia. The myoclonus must be present for at least one year by history. 2) Age > 18. 3). Patients may be treated with other medications for myoclonus, including clonazepam, valproic acid, and phenobarbital. All medications must remain stable for a period of 4 weeks prior to screening. 4) Women of childbearing age must not be pregnant, and must use adequate birth control for the duration of the study. 5) Patients must have clinically significant dystonia. 6) Patients must be able and willing to comply with the study visits and procedures. 7) Patients must be able to give informed consent.
  • the following patients are excluded from the study: 1) Patients with a clinically significant medical condition, including hepatic or renal disease. 2) Patients with a MMSE score of ⁇ 24. 3) Patients with a history of a clinically significant psychiatric illness, including major depression and psychosis. 4) Patients unwilling to abstain from alcohol for the duration of the study. 5) Patients with a history of substance abuse. 6) Patients who do not demonstrate willingness and ability to comply with all aspects of he protocol, including drug accountability.
  • the primary outcome measures of the study are the change in the UMRS.
  • the UMRS is a statistically validated comprehensive clinical rating tool for evaluating patients with myoclonus.
  • Videotapes of the UMRS are performed at each patient visit.
  • the videotapes and UMRS forms are collected, and rated by two raters who are blinded to patients' treatment status. Ratings will be entered into a database, and analyzed by a biostatistician.
  • the following assessments are performed periodically throughout the study: medical and neurological history, physical exam, vital signs, laboratory tests, pregnancy test, lead, EKG, UMRS, MMSE, depression inventory, adverse events, concomitant therapy, drug compliance.
  • AU UMRS examinations are videotaped, and observers who are blinded to patient's treatment status score the videotapes.
  • Visits in the open-label dose-ranging phase will occur at three months, six months and one year. Assessments at these visits will include those performed at the screening visit.
  • Patient 1 A 37-year-old woman with a history of asthma suffered a cardiopulmonary arrest after a drug overdose at age 31, emerging from coma with severe PHM. On initial evaluation at our center at age 33, action and intention myoclonus were severe, with prominent vocal myoclonus and disabling negative myoclonic jerks of the trunk and legs. Her mother noted that ingestion of two glasses of wine noticeably improved her myoclonus, allowing her to assist in daily hygiene activities. Nine months prior to enrollment she sustained a subcortical infarct during a hospitalization for pneumonia, leaving her with a i residual left hemiparesis.
  • Patient 2 A 25 -year-old man presented to our medical center for evaluation of a seven-year history of myoclonic jerks. His family history was notable for a paternal grandmother with torticollis and two paternal first cousins with myoclonus, all ethanol-responsive; the patient however never consumed ethanol. Genetic testing revealed a mutation in the epsilon-sarcoglycan gene, confirming the diagnosis of MD. Klein C, et al. Am J Hum Genet 67:1314-9 (2000). Prominent proximal myoclonic jerks of the head, neck, and arms were triggered by voluntary actions such as pouring or writing.
  • Patient 3 A 20-year-old man presented at age 11 to our center for initial evaluation of myoclonus that began at age 2 1 A in his right foot. Myoclonic jerks of the trunk and proximal arms interfered with writing, pouring and using utensils. At age 17 he developed obsessive-compulsive symptoms that were successfully treated with paroxetine. Genetic testing revealed a mutation in the epsilon-sarcoglycan gene, confirming the diagnosis of MD. Klein C, et al. Am J Hum Genet 67:1314-9 (2000) On several occasions he consumed ethanol, observing a dose-dependent improvement in myoclonus (requiring 80 gm of alcohol to reach maximal improvement).
  • Patient 4 A 67-year-old man with a family history of ET developed mild kinetic tremor of his hands in high school. Tremor progressively affected his ability to eat with utensils, hold a cup and write. His tremor was somewhat alcohol-responsive with moderate tremor relief fifteen minutes after ingestion of one glass of wine, and near-complete tremor relief from two glasses. He chose not to take daily medication for his ET. Three years prior to enrollment he developed cervical dystonia that also responded to ethanol, and began receiving botulinum toxin injections. The last injection was performed seven weeks prior to enrollment.
  • Patient 5 A 75-year-old retired general surgeon developed a kinetic tremor of his hands at age 62, forcing him to retire. Action tremor of the hands became progressively severe, causing social embarrassment when eating in public. Because of severe chronic obstructive pulmonary disease, treatment with propranolol was contraindicated, and primidone was too sedating. He was not currently taking any medications for his pulmonary disease, which might worsen his tremor. He drank one or two glasses of wine on social occasions, with mild improvement in his tremor.
  • Sections 1-6 of the UMRS appear above. Full details regarding the scale are available in reference 16. Higher scores indicate more severe involuntary movements. The range for each section appears in brackets ⁇ ⁇ .
  • Patients were maintained on a dose of 1 gm twice per day (taken four to five hours apart, typically after breakfast and lunch) until their next office visit two weeks later, when the examination and videotaping were repeated one hour after receiving 2 gm of sodium oxybate by mouth (4 ml of 0.5 gm/ml solution dissolved in 60 ml of water). After two weeks taking 2 gm twice daily, the procedure was repeated after a 3 gm office dose, and finally two weeks after receiving 3 gm twice daily, the procedure was repeated after a 4 gm office dose. The maximum dose allowed in the trial was 4 gm twice daily. Patients and the senior author determined at each visit whether or not to proceed to the next dose level, based principally on their ability to tolerate the most recent dose regimen. After deciding on a maximum tolerated dose, patients received a dose in the office 0.5 gm less and the examination was videotaped.
  • Tolerability Transient headache and dizziness were common and did not require dose reduction (Table 2). All patients experienced dose-limiting sedation or emotional lability, however the dose at which this occurred varied from 2 to 4 gms between patients. These side effects resolved for each patient when the individual dose was reduced by 0.5 gm.
  • Myoclonus Patients (#s 1-3): In three myoclonus patients, myoclonus at rest (section 2 of the UMRS) and stimulus-sensitive myoclonus (section 3) improved in dose- dependent fashion, (Table 3 a-c). Action myoclonus (section 4) improved by 50%, 57% and 88% respectively, while functional performance (section 5) improved by 40%, 60% and 25% (videotape segments 1-3). Patient self-assessment scores improved for patients #2 and 3, and were unchanged for patient #1. Physician global assessment scores (UMRS part 6) were "mild" (1 out of 4) for patients #2 and 3 and remained unchanged throughout the trial, while scores decreased from severe disability (4) to moderate impairment (2) in patient #1.
  • Essential tremor scores (patients #4, 5): Blinded videotape review revealed dose-dependent improvement in sustention tremor and action tremor (Table 3d and e) of 79% in patient #4, and 48% in patient #5. Scores for rest tremor were not calculated, as rest tremor was absent in one patient and mild in the other. Blinded rating of the severity of torticollis in patient #4 decreased from "moderate" to "mild" at the 1 gm twice-daily dose.
  • Patient #4's examination before treatment revealed a classic kinetic tremor with writing, using a spoon, and with drinking. After 2 gm of sodium oxybate, tremor amplitude was markedly diminished. Patient #5's kinetic tremor on pouring, using a spoon, and drinking were more severe. Although still present after receiving 2 gm of sodium oxybate, the amplitude has diminished and voluntary movements are more fluid.
  • sodium oxybate produced dose-dependent improvements in blinded ratings of ethanol-responsive myoclonus and tremor.
  • the drug was tolerated at doses that produced clinical benefit.
  • the most common side effect was sedation, which was also dose-dependent, however the dose that produced clinical benefit was lower than the sedation-limiting dose.
  • Xyrem® is currently approved in the United States only for treatment of cataplexy in narcoleptic patients. All patients who receive Xyrem® must be enrolled in the Xyrem® Success Program, a central registry that monitors and distributes the drug. Fuller, D.E., et al. Drug Sqf ' 27:293-306 (2004). The Xyrem® Success Program has ensured appropriate and safe use of the drug with no incidents of diversion or inappropriate use. Stahl P., et al. Sleep 27(suppl): A247 (2004). Sodium oxybate should not be used in patients with movement disorders outside of a protocol approved by a medical center's institutional review board.
  • GEB Gamma-hydroxybutyric acid
  • GABA gamma-aminobutyric acid
  • GHB receptor is distinct from the GABA-B receptor and when given as a drug, it is likely that some GHB is converted to GABA.
  • Sodium oxybate may act via the GABA-B receptor, either directly or via conversion to GABA.
  • GABA-B agonists such as baclofen do not improve ET or myoclonus, and clonazepam has minimal effect on ET, suggesting that other mechanisms may be involved.
  • Reticular reflex PHM is sufficiently rare that a double blind, placebo-controlled trial of sodium oxybate in this patient population may not be feasible. It therefore seems reasonable to consider a test dose of ethanol in these patients if standard anti-myoclonic drugs fail. Patients who respond to ethanol might also benefit from treatment with sodium oxybate. Myoclonus also improved in our two patients with MD, a finding similar to Prion's observation. Priori, A., et al. Neurology 54:1706(2000). However given the risk of ethanol abuse in the MD population, the long-term tolerability of sodium oxybate must be established before it can be recommended as a treatment for MD patients.
  • DBS Deep brain stimulation
  • Bilateral stimulation is typically required for head tremor and voice tremor, and the unavoidable but small operative risks of DBS and the possibility of delayed lead failure or infection are a concern.
  • This invention provides for methods of treating patients with other alcohol-responsive movement disorders with the compound of Formula I and other compounds of the invention.
  • the invention provides also for methods to assess whether movement disorders that do not benefit from ethanol (for example half of all patients with ET) will benefit from treatment. If not, then the response to the drug may reveal potential differences in pathogenesis between responsive and non-responsive patients.
  • Table 1 Clinical features of the twenty patients are summarized in this table.
  • Dx diagnosis; Age: in years at time of enrollment 1 Sx 1 symptom duration in years at time of enrollment; Current meds: continued at time of enrollment; Past meds: medications taken in the past for treatment of involuntary movements (excluding those currently being administered), Rx?: decision (Yes or No) to continue treatment with sodium oxybate after completion of the trial; Dose: total daily dose of sodium oxybate on completion of the trial
  • R arm (flexor surface of wrist)
  • Sections 1-6 of the UMRS appear above. Full details regarding the scale are available in reference 16. Higher scores indicate more severe involuntary movements. The range for each section appears in brackets ⁇ ⁇ .
  • a patient with ET (patient #15) was observed and video-recorded pouring water from one cup to another at 15-minute intervals after receiving 1.5 gm of sodium oxybate in the office. Improvement in action tremor during pouring was evident at 45 minutes and obvious at 60 minutes after treatment. Prior to treatment, tremor during tasks (drawing and sipping water from spoon) was also evident in patient #17 displaying ET ( Figure 4). Improvement in kinetic tremor during tasks was evident after being treated with sodium oxybate ( Figure 4).
  • Table 2 Kinetic and postural tremor scores at various individual doses of sodium oxybate are displayed in the second and third columns from the left. Scores at various individual doses of sodium oxybate for myoclonus at rest, stimulus-sensitive myoclonus, action myoclonus and functional performance are displayed in the fifth through the eight columns from the left. P values are displayed in italics for each score relative to pre-treatment values: values ⁇ 0.05 are noted with the symbol *, and values ⁇ 0.01 with the symbol **.
  • the average final daily dose of sodium oxybate for patients with myoclonus was 6.5 gm, (range 3-9 gm) and 4.3 gm for ET, (range 1.5-7.5 gm).
  • Dose titration was stopped in two patients due to adequate benefit, or was limited by sedation (60%) or ataxia (20%). These side effects resolved when the dose was reduced to the previous level. Fourteen patients chose to continue the drag after completing the trial.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des méthodes de traitement de troubles moteurs consistant à administrer une quantité efficace du composé représenté par la formule (I) à un patient nécessitant un tel traitement. Cette invention concerne plus particulièrement une méthode de traitement de la myoclonie consistant à administrer à un patient un composé représenté par la formule (I), la myoclonie n'étant pas une myoclonie essentielle sensible à l'alcool avec dystonie. Dans certains modes de réalisation, la myoclonie est une myoclonie post-hypoxique. Cette invention concerne également une méthode de traitement de la dystonie, du tremblement essentiel, du tremblement cérébelleux, d'un tic ou de la chorée, laquelle méthode consiste à administrer à un patient un composé représenté par la formule (I).
PCT/US2005/040877 2004-11-10 2005-11-09 Methode de traitement de troubles moteurs WO2006053186A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/667,530 US20090137565A1 (en) 2004-11-10 2005-11-09 Method for treatment of movement disorders
MX2007005679A MX2007005679A (es) 2004-11-10 2005-11-09 Metodo para tratamiento de desordenes de movimiento.
CA002586975A CA2586975A1 (fr) 2004-11-10 2005-11-09 Methode de traitement de troubles moteurs
AU2005304352A AU2005304352A1 (en) 2004-11-10 2005-11-09 Method for treatment of movement disorders
EP05847768A EP1809286A4 (fr) 2004-11-10 2005-11-09 Methode de traitement de troubles moteurs
JP2007541338A JP2008519847A (ja) 2004-11-10 2005-11-09 運動障害の治療方法
IL182906A IL182906A0 (en) 2004-11-10 2007-05-01 Method for treatment of movement disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62664504P 2004-11-10 2004-11-10
US60/626,645 2004-11-10

Publications (2)

Publication Number Publication Date
WO2006053186A2 true WO2006053186A2 (fr) 2006-05-18
WO2006053186A3 WO2006053186A3 (fr) 2006-08-10

Family

ID=36337239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040877 WO2006053186A2 (fr) 2004-11-10 2005-11-09 Methode de traitement de troubles moteurs

Country Status (10)

Country Link
US (1) US20090137565A1 (fr)
EP (1) EP1809286A4 (fr)
JP (1) JP2008519847A (fr)
KR (1) KR20070085838A (fr)
CN (1) CN101098701A (fr)
AU (1) AU2005304352A1 (fr)
CA (1) CA2586975A1 (fr)
IL (1) IL182906A0 (fr)
MX (1) MX2007005679A (fr)
WO (1) WO2006053186A2 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053691A1 (fr) 2008-11-04 2010-05-14 Jazz Pharmaceuticals, Inc. Formes posologiques à libération immédiate d'oxybate de sodium
US8772306B1 (en) 2013-03-01 2014-07-08 Jazz Pharmaceuticals, Inc. Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
WO2017168059A1 (fr) 2016-04-01 2017-10-05 Debregeas Et Associes Pharma Doses unitaires à libération immédiate de ghb ou de l'un de ses sels thérapeutiquement acceptables administrées par voie orale et leur utilisation pour maintenir l'abstinence alcoolique.
US10272062B2 (en) 2016-07-22 2019-04-30 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
WO2019183536A1 (fr) * 2018-03-22 2019-09-26 Research Foundation Of The City University Of New York Modulation de nkcc1 neuronal en tant que stratégie thérapeutique de la spasticité et des troubles apparentés
US10457627B2 (en) 2015-09-23 2019-10-29 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10758488B2 (en) 2010-03-24 2020-09-01 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10925844B2 (en) 2019-03-01 2021-02-23 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
US11426373B2 (en) 2017-03-17 2022-08-30 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8702629B2 (en) * 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101919811A (zh) * 2009-06-09 2010-12-22 北京博时安泰液体制剂科技有限公司 一种左乙拉西坦注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) * 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) * 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
JPS60168044A (ja) * 1984-02-10 1985-08-31 Sharp Corp 感湿素子
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) * 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US5145682A (en) * 1986-05-30 1992-09-08 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
ATE238783T1 (de) * 1998-12-23 2003-05-15 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
AU2001291173A1 (en) * 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1809286A4 *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795567B2 (en) 2008-11-04 2017-10-24 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
WO2010053691A1 (fr) 2008-11-04 2010-05-14 Jazz Pharmaceuticals, Inc. Formes posologiques à libération immédiate d'oxybate de sodium
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP3470067A1 (fr) 2008-11-04 2019-04-17 Jazz Pharmaceuticals, Inc. Formes posologiques d'oxybate de sodium à libération immédiate
US11207270B2 (en) 2010-03-24 2021-12-28 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10987310B2 (en) 2010-03-24 2021-04-27 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10813885B1 (en) 2010-03-24 2020-10-27 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10959956B2 (en) 2010-03-24 2021-03-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10966931B2 (en) 2010-03-24 2021-04-06 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10758488B2 (en) 2010-03-24 2020-09-01 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US11090269B1 (en) 2010-03-24 2021-08-17 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10213400B2 (en) 2013-03-01 2019-02-26 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US8952029B2 (en) 2013-03-01 2015-02-10 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9486426B2 (en) 2013-03-01 2016-11-08 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US8772306B1 (en) 2013-03-01 2014-07-08 Jazz Pharmaceuticals, Inc. Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US11253494B2 (en) 2013-03-01 2022-02-22 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10864181B2 (en) 2013-03-01 2020-12-15 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US11986446B2 (en) 2013-03-01 2024-05-21 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11077079B1 (en) 2015-02-18 2021-08-03 Jazz Pharmaceuticals Ireland Limited GHB formulation and method for its manufacture
US11364215B1 (en) 2015-02-18 2022-06-21 Jazz Pharmaceuticals Ireland Limited GHB formulation and method for its manufacture
US11147782B1 (en) 2015-02-18 2021-10-19 Jazz Pharmaceuticals Ireland Limited GHB formulation and method for its manufacture
US10501401B2 (en) 2015-09-23 2019-12-10 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10774031B2 (en) 2015-09-23 2020-09-15 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10941107B2 (en) 2015-09-23 2021-03-09 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
US10457627B2 (en) 2015-09-23 2019-10-29 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
FR3049463A1 (fr) * 2016-04-01 2017-10-06 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
IL261618A (en) * 2016-04-01 2018-10-31 Debregeas Et Associes Pharma Dosage unit for immediate release of ghb or one of its medically acceptable salts, given orally and used to maintain abstinence from alcohol
EA037591B1 (ru) * 2016-04-01 2021-04-19 Дебрежа Э Ассосье Фарма Применение пероральной фармацевтической формы с немедленным высвобождением, содержащей гидроксимасляную кислоту или одну из ее терапевтически приемлемых солей, для поддержания отказа от алкоголя
WO2017168059A1 (fr) 2016-04-01 2017-10-05 Debregeas Et Associes Pharma Doses unitaires à libération immédiate de ghb ou de l'un de ses sels thérapeutiquement acceptables administrées par voie orale et leur utilisation pour maintenir l'abstinence alcoolique.
US11690816B2 (en) 2016-04-01 2023-07-04 Debregeas Et Associes Pharma Unit doses for immediate release of GHB or of one of the therapeutically acceptable salts thereof, administered orally, and the use thereof to maintain alcohol abstinence
AU2017240266B2 (en) * 2016-04-01 2022-12-01 Debregeas Et Associes Pharma Unit doses for immediate release of GHB or of one of the therapeutically acceptable salts thereof, administered orally, and the use thereof to maintain alcohol abstinence.
CN108697676A (zh) * 2016-04-01 2018-10-23 D&A制药 Ghb或其一种治疗上可接受的盐的立即释放的口服给药的单位剂量及其维持酒精戒断的用途
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10952986B2 (en) 2016-07-22 2021-03-23 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11065224B2 (en) 2016-07-22 2021-07-20 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10272062B2 (en) 2016-07-22 2019-04-30 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10736866B2 (en) 2016-07-22 2020-08-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10973795B2 (en) 2016-07-22 2021-04-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11052061B2 (en) 2016-07-22 2021-07-06 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11426373B2 (en) 2017-03-17 2022-08-30 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US11986659B2 (en) 2018-03-22 2024-05-21 Research Foundation Of The City University Of New York Modulation of neuronal NKCC1 as a therapeutic strategy for spasticity and related disorders
WO2019183536A1 (fr) * 2018-03-22 2019-09-26 Research Foundation Of The City University Of New York Modulation de nkcc1 neuronal en tant que stratégie thérapeutique de la spasticité et des troubles apparentés
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US10925844B2 (en) 2019-03-01 2021-02-23 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
EP1809286A2 (fr) 2007-07-25
EP1809286A4 (fr) 2010-09-01
JP2008519847A (ja) 2008-06-12
US20090137565A1 (en) 2009-05-28
WO2006053186A3 (fr) 2006-08-10
CN101098701A (zh) 2008-01-02
KR20070085838A (ko) 2007-08-27
CA2586975A1 (fr) 2006-05-18
AU2005304352A1 (en) 2006-05-18
MX2007005679A (es) 2007-07-11
IL182906A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
US20090137565A1 (en) Method for treatment of movement disorders
US9114140B2 (en) Integrated neuromodulation system for mood enhancement of a living human subject
JPH10505864A (ja) 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
TW200936127A (en) Use of cannabinoids in combination with an anti-psychotic medicament
WO2003092682A1 (fr) Utilisation de zonisamide dans le traitement de l'obesite et des troubles alimentaires
JP2002509104A (ja) 遅発性ジスキネジア及び他の運動障害の治療方法
Chawla et al. Neurologic effects of caffeine
EP1707194A1 (fr) Composition soulageant le stress
EP2037964A2 (fr) Preparation combinees contenant du bifeprunox et un agoniste de la dopamine
US20230145635A1 (en) Treatment of menstrual cycle-induced symptoms
TWI334780B (en) Method of treating movement disorders using barbituric acid derivatives
Taddei et al. New symptomatic treatments for the management of motor and nonmotor symptoms of Parkinson's disease
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
JP2002500181A (ja) ジスキネジーの処置
JP2021513977A (ja) レストレスレッグズ症候群を治療するための治療薬
JP2009539941A (ja) Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
Dreyer Pharmacology for nurses and other health workers
EP2891491A1 (fr) Utilisation de (r) -phénylpiracétame pour le traitement de troubles du sommeil
RU2165759C1 (ru) Средство для лечения алкогольной интоксикации
EP4376954A1 (fr) Lemborexant destiné à être utilisé dans des procédés de traitement d'un trouble du rythme sommeil/réveil et de troubles du rythme circadien associés à des maladies neurodégénératives
WO2021026071A1 (fr) Méthode de traitement d'une dysfonction sexuelle
TW202131910A (zh) 使用mtorc1調節劑的治療方法
CA3026043A1 (fr) Compositions therapeutiques et methodes
Morgenthaler et al. Scientific Reports on GHB
Kamath Study of Anticonvulsant effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model In Albino Mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005847768

Country of ref document: EP

Ref document number: 182906

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2586975

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/005679

Country of ref document: MX

Ref document number: 2007541338

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005304352

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005304352

Country of ref document: AU

Date of ref document: 20051109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 555536

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020077012803

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 4384/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580042423.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005847768

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11667530

Country of ref document: US